Compare iShares MSCI Hong Kong ETF (EWH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.04, while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWH | INO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $2.87 |
52-Week Low | $20.15 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.05, up 1.75% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF tracks Hong Kong equities, with recent momentum in Chinese tech stocks supporting performance. A dividend of $0.35 is scheduled for June 2026. Support and resistance cluster tightly around $22, indicating a critical price zone.
Outlook hinges on Hang Seng Index momentum and China's economic policies. Risks include regulatory scrutiny on Chinese firms and Asian market volatility. Analyst sentiment is mixed, with technical strength countered by valuation concerns in global markets.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
